Chronic Airways Assessment Test: Psychometric properties in patients with asthma and/or COPD

Erin L.  Tomaszewski; Mark J.  Atkinson; Christer Janson; Niklas Karlsson; Barry Make; David Price; Helen K.  Reddel; NOVELTY study investigators; NOVELTY Scientific Community

doi:10.1186/s12931-023-02394-6

Chronic Airways Assessment Test: Psychometric properties in patients with asthma and/or COPD

Erin L. Tomaszewski^* (Corresponding Author), Mark J. Atkinson, Christer Janson, Niklas Karlsson, Barry Make, David Price, Helen K. Reddel, NOVELTY study investigators, NOVELTY Scientific Community

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

2 Downloads (Pure)

Abstract

Background: No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT).
Methods: The psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma+COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning and
analysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma+COPD and those with COPD.
Results: CAAT items were internally consistent (Cronbach’s alpha: >0.7) within each diagnostic group (n=510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N=277, Pearson’s correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4– 0.7) to strongly (>0.7) with other PRO measures and weakly (Conclusions: CAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice.

Original language	English
Article number	106
Number of pages	13
Journal	Respiratory Research
Volume	24
Early online date	8 Apr 2023
DOIs	https://doi.org/10.1186/s12931-023-02394-6
Publication status	Published - 8 Apr 2023

Bibliographical note

Acknowledgements
The authors would like to thank the patients who participated in this study and wish to acknowledge the work of the NOVELTY Scientific Community and the NOVELTY study investigators, who are listed in full below, and Sharon MacLachlan (Evidera, London, UK), who participated in the analysis of sections of the data. Medical writing support, under the direction of the authors, was provided by Niall Tyrer, MBiolSci, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175(9):1298–1304).
Funding
The NOVELTY study was funded by AstraZeneca.

Keywords

Asthma
COPD
patient-reported
psychometrics
chronic airways assessment test
COPD assessment test

Access to Document

10.1186/s12931-023-02394-6Licence: CC BY

Tomaszewski_etal_RR_Chronic_Airways_Assessment_VoR
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Final published version, 1.12 MBLicence: CC BY

Cite this

@article{f34885e4fbb94725932b086f1851d40c,

title = "Chronic Airways Assessment Test: Psychometric properties in patients with asthma and/or COPD ",

abstract = "Background: No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT).Methods: The psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma+COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning andanalysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma+COPD and those with COPD.Results: CAAT items were internally consistent (Cronbach{\textquoteright}s alpha: >0.7) within each diagnostic group (n=510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N=277, Pearson{\textquoteright}s correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4– 0.7) to strongly (>0.7) with other PRO measures and weakly (Conclusions: CAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice.",

keywords = "Asthma, COPD, patient-reported, psychometrics, chronic airways assessment test, COPD assessment test",

author = "Tomaszewski, {Erin L.} and Atkinson, {Mark J.} and Christer Janson and Niklas Karlsson and Barry Make and David Price and Reddel, {Helen K.} and {NOVELTY study investigators} and {NOVELTY Scientific Community}",

note = "Acknowledgements The authors would like to thank the patients who participated in this study and wish to acknowledge the work of the NOVELTY Scientific Community and the NOVELTY study investigators, who are listed in full below, and Sharon MacLachlan (Evidera, London, UK), who participated in the analysis of sections of the data. Medical writing support, under the direction of the authors, was provided by Niall Tyrer, MBiolSci, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175(9):1298–1304). Funding The NOVELTY study was funded by AstraZeneca.",

year = "2023",

month = apr,

day = "8",

doi = "10.1186/s12931-023-02394-6",

language = "English",

volume = "24",

journal = "Respiratory Research",

issn = "1465-9921",

publisher = "BioMed Central",

}

TY - JOUR

T1 - Chronic Airways Assessment Test

T2 - Psychometric properties in patients with asthma and/or COPD

AU - Tomaszewski, Erin L.

AU - Atkinson, Mark J.

AU - Janson, Christer

AU - Karlsson, Niklas

AU - Make, Barry

AU - Price, David

AU - Reddel, Helen K.

AU - NOVELTY study investigators

AU - NOVELTY Scientific Community

N1 - Acknowledgements The authors would like to thank the patients who participated in this study and wish to acknowledge the work of the NOVELTY Scientific Community and the NOVELTY study investigators, who are listed in full below, and Sharon MacLachlan (Evidera, London, UK), who participated in the analysis of sections of the data. Medical writing support, under the direction of the authors, was provided by Niall Tyrer, MBiolSci, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175(9):1298–1304). Funding The NOVELTY study was funded by AstraZeneca.

PY - 2023/4/8

Y1 - 2023/4/8

N2 - Background: No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT).Methods: The psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma+COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning andanalysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma+COPD and those with COPD.Results: CAAT items were internally consistent (Cronbach’s alpha: >0.7) within each diagnostic group (n=510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N=277, Pearson’s correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4– 0.7) to strongly (>0.7) with other PRO measures and weakly (Conclusions: CAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice.

AB - Background: No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT).Methods: The psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma+COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning andanalysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma+COPD and those with COPD.Results: CAAT items were internally consistent (Cronbach’s alpha: >0.7) within each diagnostic group (n=510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N=277, Pearson’s correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4– 0.7) to strongly (>0.7) with other PRO measures and weakly (Conclusions: CAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice.

KW - Asthma

KW - COPD

KW - patient-reported

KW - psychometrics

KW - chronic airways assessment test

KW - COPD assessment test

U2 - 10.1186/s12931-023-02394-6

DO - 10.1186/s12931-023-02394-6

M3 - Article

C2 - 37031164

SN - 1465-9921

VL - 24

JO - Respiratory Research

JF - Respiratory Research

M1 - 106

ER -

Chronic Airways Assessment Test: Psychometric properties in patients with asthma and/or COPD

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this